Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study-Reference-Cited by-同舟云学术

Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study

Published:2022-08 Issue:8 Volume:9 Page:e544-e553
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Schramm Birgit,Temfack Elvis,Descamps Diane,Nicholas Sarala,Peytavin Gilles,Bitilinyu-Bangoh Joseph E,Storto Alexandre,Lê Minh P,Abdi Basma,Ousley Janet,Kalua Thokozani,Calvez Vincent,Jahn Andreas,Marcelin Anne-Geneviève,Szumilin Elisabeth

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference27 articles.

1. HIV drug resistance—an emerging threat to epidemic control;Beyrer;N Engl J Med,2017

2. Impact of HIV drug resistance on HIV/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in sub-Saharan Africa;Phillips;J Infect Dis,2017

3. The fourth HIV epidemic;Laborde-Balen;Lancet Infect Dis,2018

4. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis;Kanters;Lancet HIV,2016

5. A systematic review of the genetic mechanisms of dolutegravir resistance;Rhee;J Antimicrob Chemother,2019

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia;PLOS ONE;2024-09-06

2. Impact of financial incentives on viral suppression among adults initiating HIV treatment in Tanzania: a hybrid effectiveness–implementation trial;The Lancet HIV;2024-09

3. Three Year Outcomes after Programmatic Transitioning to Dolutegravir in the Context of Severe Civil Unrest in Haiti;2024-08-14

4. Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir;Viruses;2024-07-19

5. Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia;Clinical Infectious Diseases;2024-06-07